AFF1 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 5 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain ALK status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 9 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 7 are open and 2 are closed. Of the trials that contain BCL2 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [3].

BCL6 is an inclusion eligibility criterion in 9 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 7 are open and 2 are closed. Of the trials that contain BCL6 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IRF4 is an inclusion eligibility criterion in 2 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 10 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 8 are open and 2 are closed. Of the trials that contain MYC status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].